AbbVie Buys $1.45B Option on Kestrel's KRAS Program
AbbVie has secured an exclusive right to buy Kestrel Therapeutics for up to $1.45 billion, with the biotech required to hit unspecified development and…
AbbVie has secured an exclusive right to buy Kestrel Therapeutics for up to $1.45 billion, with the biotech required to hit unspecified development and…
Survodutide posted 13.4% placebo-controlled weight loss at 76 weeks in the SYNCHRONIZE-1 Phase 3 trial, solid enough to clear both primary endpoints, but…
Incyte will file for FDA approval of povorcitinib, its oral JAK1 inhibitor pill, in nonsegmental vitiligo after the drug hit in both of its Phase 3 trials.
FDA proposed to rescind the approval of Tavneos, Amgen's oral treatment for ANCA-associated vasculitis, after CDER concluded that data from the drug's…
Federal prosecutors charged a 19-year-old dual U.S.-Estonian citizen with wire fraud, conspiracy, and computer intrusion, alleging he's a prolific member of…
Rezzayo passed phase 3.
Sun Pharma paid $11.75 billion, or $14 a share in cash, to buy Organon in a deal that positions the India-based generics maker among the world's biosimilar…
Intellia Therapeutics filed a rolling biologics license application for lonvo-z Monday, backed by Phase 3 data showing an 87% reduction in hereditary…
Eli Lilly paid up to $2.3 billion for Ajax Therapeutics on April 27, adding a Phase 1 myelofibrosis asset to a deal streak that's included Verve ($1B…
Intellia began a rolling FDA submission for lonvoguran ziclumeran (lonvo-z) Monday after phase 3 data showed a single infusion reduced hereditary angioedema…
Evan Tangeman, 22, was sentenced to 70 months in federal prison for laundering at least $3.5 million tied to a $230 million Bitcoin heist, a RICO conspiracy…
FDA issued Commissioner's National Priority Vouchers to three companies developing psilocybin and methylone therapies Friday, cutting review timelines from…
ADT and the ShinyHunters extortion group are at a standoff today, with attackers threatening to publish 10 million customer records unless the home security…
FDA issued fast-track vouchers to three psychedelic-focused companies Friday, and the selections hit Wall Street as a surprise.
Eli Lilly bought an in vivo CAR-T biotech, terms undisclosed.